These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 22515959)
1. XAGE-1a and XAGE-1d are potential biomarkers of lung squamous cell carcinoma. Ha JS; Sung HY; Kim SY; Lim HM; Kim HK; Park SS Clin Chim Acta; 2012 Aug; 413(15-16):1226-31. PubMed ID: 22515959 [TBL] [Abstract][Full Text] [Related]
2. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer. Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer. Okamura K; Takayama K; Izumi M; Harada T; Furuyama K; Nakanishi Y Lung Cancer; 2013 Apr; 80(1):45-9. PubMed ID: 23352032 [TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of SCC, CEA and CYFRA 21.1 in lung cancer: a Bayesian analysis. Pastor A; Menéndez R; Cremades MJ; Pastor V; Llopis R; Aznar J Eur Respir J; 1997 Mar; 10(3):603-9. PubMed ID: 9072992 [TBL] [Abstract][Full Text] [Related]
5. Utility of squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra 21-1 and neuron specific enolase in lung cancer diagnosis: a prospective study from China. Song WA; Liu X; Tian XD; Wang W; Liang CY; Zhang T; Guo JT; Peng YH; Zhou NK Chin Med J (Engl); 2011 Oct; 124(20):3244-8. PubMed ID: 22088515 [TBL] [Abstract][Full Text] [Related]
6. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer. Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815 [TBL] [Abstract][Full Text] [Related]
7. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Holdenrieder S; von Pawel J; Dankelmann E; Duell T; Faderl B; Markus A; Siakavara M; Wagner H; Feldmann K; Hoffmann H; Raith H; Nagel D; Stieber P Clin Cancer Res; 2008 Dec; 14(23):7813-21. PubMed ID: 19047109 [TBL] [Abstract][Full Text] [Related]
8. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients. Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320 [TBL] [Abstract][Full Text] [Related]
9. [Detection and diagnostic value of serum carcinoembryonic antigen and cytokeratin 19 fragment in lung cancer patients]. Hang ZQ; Zheng MF; Huang JH Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):847-9. PubMed ID: 22335951 [TBL] [Abstract][Full Text] [Related]
10. Usefulness of serum anti-p53 antibody assay for lung cancer diagnosis. Park Y; Kim Y; Lee JH; Lee EY; Kim HS Arch Pathol Lab Med; 2011 Dec; 135(12):1570-5. PubMed ID: 22129186 [TBL] [Abstract][Full Text] [Related]
11. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study. Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259 [TBL] [Abstract][Full Text] [Related]
12. Value of tumour and inflammatory markers in lung cancer. Oremek GM; Sauer-Eppel H; Bruzdziak TH Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794 [TBL] [Abstract][Full Text] [Related]
13. Utility of serum cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA) as tumour markers for non-small cell lung cancer. Chantapet P; Riantawan P; Lebnak P; Getngern P J Med Assoc Thai; 2000 Apr; 83(4):383-91. PubMed ID: 10808698 [TBL] [Abstract][Full Text] [Related]
14. The significance of ferritin, lipid-associated sialic acid, CEA, squamous cell carcinoma (SCC) antigen, and CYFRA 21-1 levels in SCC of the head and neck. Inal E; Laçin M; Asal K; Ceylan A; Köybaşioğlu A; Ileri F; Uslu SS Kulak Burun Bogaz Ihtis Derg; 2004; 12(1-2):23-30. PubMed ID: 16010093 [TBL] [Abstract][Full Text] [Related]
15. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer. Nisman B; Amir G; Lafair J; Heching N; Lyass O; Peretz T; Barak V Anticancer Res; 1999; 19(4C):3549-52. PubMed ID: 10629651 [TBL] [Abstract][Full Text] [Related]
16. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443 [TBL] [Abstract][Full Text] [Related]
17. Assessment of serum CYFRA 21-1 in lung cancer. Muraki M; Tohda Y; Iwanaga T; Uejima H; Nagasaka Y; Nakajima S Cancer; 1996 Apr; 77(7):1274-7. PubMed ID: 8608502 [TBL] [Abstract][Full Text] [Related]
18. [The value of plasma pro-gastrin-releasing peptide, cytokeratin 19-fragments and carcinoembryonic antigen in patients with lung cancer]. Chen YJ; Jin WD; Yang GY; Zhou YL Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Oct; 25(5):381-3. PubMed ID: 22338231 [TBL] [Abstract][Full Text] [Related]
19. Serum tumor marker CYFRA 21-1 in the diagnostics of squamous cell lung cancer--comparison with CEA. Berzinec P; Zuffová H; Letkovicová M; Arpásová M Neoplasma; 1996; 43(3):159-61. PubMed ID: 8841502 [TBL] [Abstract][Full Text] [Related]
20. Performance characteristics of an automated assay for the quantitation of CYFRA 21-1 in human serum. Patel JL; Erickson JA; Roberts WL; Grenache DG Clin Biochem; 2010 Dec; 43(18):1449-52. PubMed ID: 20875814 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]